There's no question about where Illumina, Inc. (NASDAQ: ILMN) stands today. The company is the undisputed leader in genomic sequencing. Illumina recently reported its highest sequencing instrument sales in years thanks to new products introduced in 2017 and 2018. And despite its share price falling in the midst of the broader market pullback, Illumina stock is still up close to 40% so far this year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,